LLY

986.47

-0.29%↓

JNJ

228.5

+1.02%↑

ABBV

208.59

+0.06%↑

UNH

388.01

+0.71%↑

AZN

184.28

+0.75%↑

LLY

986.47

-0.29%↓

JNJ

228.5

+1.02%↑

ABBV

208.59

+0.06%↑

UNH

388.01

+0.71%↑

AZN

184.28

+0.75%↑

LLY

986.47

-0.29%↓

JNJ

228.5

+1.02%↑

ABBV

208.59

+0.06%↑

UNH

388.01

+0.71%↑

AZN

184.28

+0.75%↑

LLY

986.47

-0.29%↓

JNJ

228.5

+1.02%↑

ABBV

208.59

+0.06%↑

UNH

388.01

+0.71%↑

AZN

184.28

+0.75%↑

LLY

986.47

-0.29%↓

JNJ

228.5

+1.02%↑

ABBV

208.59

+0.06%↑

UNH

388.01

+0.71%↑

AZN

184.28

+0.75%↑

Home・Aandelen Lijst・Odonate Therapeutics Inc

O
Odonate Therapeutics Inc

Open

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Odonate Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 mei 2026, 23:10 UTC

Populaire aandelen

Stocks to Watch: Agilysys, XP

18 mei 2026, 18:44 UTC

Belangrijke Marktbewegers

Claritev Shares Recover After Comments About DOJ

18 mei 2026, 23:55 UTC

Winsten

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mei 2026, 23:47 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

18 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mei 2026, 23:37 UTC

Marktinformatie

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mei 2026, 22:31 UTC

Acquisities, Fusies, Overnames

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mei 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mei 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mei 2026, 22:25 UTC

Acquisities, Fusies, Overnames

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mei 2026, 22:24 UTC

Acquisities, Fusies, Overnames

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

18 mei 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

18 mei 2026, 20:25 UTC

Winsten

Correct: XP 1Q Total Client Assets BRL1.53T

18 mei 2026, 20:23 UTC

Winsten

XP 1Q Total Client Assets BRL1.53B

18 mei 2026, 20:19 UTC

Winsten

XP 1Q Adj EPS BRL2.49 >XP

18 mei 2026, 20:19 UTC

Winsten

XP 1Q Rev BRL4.73B >XP

18 mei 2026, 19:10 UTC

Marktinformatie

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mei 2026, 19:00 UTC

Winsten

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mei 2026, 18:52 UTC

Marktinformatie

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mei 2026, 18:17 UTC

Marktinformatie

Acquisities, Fusies, Overnames

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mei 2026, 17:22 UTC

Marktinformatie

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mei 2026, 16:57 UTC

Acquisities, Fusies, Overnames

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mei 2026, 16:57 UTC

Marktinformatie

Global Energy Roundup: Market Talk

18 mei 2026, 16:57 UTC

Marktinformatie

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mei 2026, 16:54 UTC

Acquisities, Fusies, Overnames

Vinci Doesn't Set Out Financial Details of Deal

18 mei 2026, 16:50 UTC

Acquisities, Fusies, Overnames

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mei 2026, 16:49 UTC

Acquisities, Fusies, Overnames

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mei 2026, 16:49 UTC

Acquisities, Fusies, Overnames

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mei 2026, 16:48 UTC

Acquisities, Fusies, Overnames

Vinci Buys Canada's Modern Group of Companies

Peer Vergelijking

Prijswijziging

Odonate Therapeutics Inc Prognose

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

EBITDA

Operationele winst

Over Odonate Therapeutics Inc

Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.